Sponsors (2)
Introduced September 3, 2025 by Todd Young · Last progress September 3, 2025
The bill directs substantial federal research funding and coordinated studies to improve biotech safety, regulatory clarity, and transparency—supporting safer innovation and benefits to researchers and industry—while imposing meaningful taxpayer costs, raising conflict-of-interest and biosafety concerns, and creating pressures toward commercialization and potential new compliance burdens.
Researchers, universities, and research staff will receive dedicated federal research funding ($50M/year, FY2026–2030; $250M total) to study environmental and health risks of biotech organisms, enabling more and sustained safety research.
Federal and state regulators (USDA, FDA, EPA and others) will get research-based data and coordinated collaboration to clarify regulatory pathways and oversight for biotech organisms, improving the basis for safety decisions.
Communities, consumers, and the environment may face lower environmental and human/animal health risks because funding priorities target monitoring, gene transfer, gene drives, and management practices that inform safer deployment and mitigation.
Taxpayers will fund the program (about $250M for FY2026–2030 plus authorized study costs ~ $1.5M), increasing federal spending and potentially diverting funds from other priorities.
Allowing industry and private entities to receive grant funding risks prioritizing commercial interests, creating conflict-of-interest or IP concerns that could shape research agendas and outcomes.
Funding and research into potentially risky topics (e.g., gene drives, gene transfer) raises biosafety and dual-use concerns that could increase biological risk if oversight is insufficient.
Based on analysis of 4 sections of legislative text.
Creates a new NSF research program to fund risk‑assessment and safety research on organisms produced with biotechnology, and directs NSF to contract the National Academies to carry out a two‑phase study comparing biotech tools and products to conventional counterparts and to recommend risk‑proportionate regulatory approaches. The bill authorizes multiyear funding for the NSF program ($50 million per year for FY2026–2030) and a smaller FY2026 authorization to pay for the Academies study, requires interagency consultation with USDA, FDA, EPA and others, and mandates public reports and an implementation plan to close identified research gaps.